Long-Term Treatment with Subcutaneous T-20, a Fusion Inhibitor, in HIV-Infected Patients: Patient Satisfaction and Impact on Activities of Daily Living

Cohen, C.J.; Dusek, A.; Green, J.; Johns, E.L.; Nelson, E.; Recny, M.A.
July 2002
AIDS Patient Care & STDs;Jul2002, Vol. 16 Issue 7, p327
Academic Journal
T-20 is a novel antiretroviral agent that inhibits the fusion of human immunodeficiency virus (HIV) with target cell membranes. It is delivered by self-administered, twice-daily, subcutaneous injections. The impact of this mode of administration on patients' ability to conduct normal activities of daily living (ADL) and comply with a T-20 treatment regimen was assessed as part of a 48-week, phase 2 trial (T20-205). Patients' opinions on the impact of T-20 on ADL, ease of use of T-20, and choice to continue with T-20 were assessed by two questionnaires completed at baseline and week 48 (or study withdrawal). ADL were measured using a Likert-type scale based on established instruments with questions added to assess HIV-specific issues. Seventy previously treated patients received T-20 in combination with an average of five oral antiretroviral agents. Relative to other HIV/AIDS drugs, T-20 had little impact on ADL, with the majority of patients (54%-96%) agreeing (somewhat or strongly) that subcutaneous injections had not limited ADL. Patients found the injections relatively easy to perform with more than 47% of patients stating that each aspect of the injections (ease of injection, storage, reconstitution, and disposal of sharps) were very easy or easy. If medically indicated, 98% of patients stated that they would choose to continue with T-20. The most common reasons for this were the perceived effectiveness of T-20 and lack of side effects. In conclusion, the need to deliver T-20 via twice-daily subcutaneous injections was not considered an important barrier by HIV-positive patients seeking improvement or stabilization of their condition.


Related Articles

  • Changes in symptoms and health-related quality of life in a nationally representative sample of adults in treatment for HIV. Lorenz, Karl A.; Cunningham, William E.; Spritzer, Karen L.; Hays, Ron D. // Quality of Life Research;Aug2006, Vol. 15 Issue 6, p951 

    Patient-centered measures of functioning and well-being are needed to monitor and improve health for HIV-infected persons. We estimated the associations between HRQOL and symptoms over time in HIV-infected persons, adjusting for demographic and clinical characteristics using a longitudinal study...

  • POZitive living with HIV. Bomba, Ed // Philadelphia Gay News;11/15/2013, Vol. 37 Issue 46, p16 

    The article discusses ways on HIV-positive people can manage their health and life to ensure a good quality of life despite the illness. It explains the management that involves not just HIV medicine, but the possible, early onset of the diseases of aging and the medicines that go with them....

  • Chapter #4: Controlling HIV and AIDS. Gedatus, Gustav Mark // HIV & AIDS (0-7368-0281-9);2000, p28 

    The chapter focuses on the importance of knowing one's HIV status to control its effects and to protect others from the virus. Testing for HIV can be done confidentially or anonymously for complete privacy. HIV-positive people need to eat right, exercise, get plenty of rest, and avoid tobacco,...

  • Uptake of antiretroviral treatment among people living with HIV in London: ethnicity, gender and sexual orientation. Elford, J.; Ibrahim, F.; Bukutu, C.; Anderson, J. // Sexually Transmitted Infections;Jun2008, Vol. 84 Issue 3, p176 

    Objective: To examine, by ethnicity, gender and sexual orientation, uptake of antiretroviral treatment among people living with HIV in London. Methods: Between June 2004 and June 2005, 1687 people living with HIV (73% response) receiving treatment and care in North East London National Health...

  • Elvitegravir non-inferior to raltegravir in treatment-experienced patients.  // Infectious Disease News;Aug2011, Vol. 24 Issue 8, p12 

    The article focuses on a study which compared the effectiveness of once-daily elvitegravir and twice-daily raltegravir in treating HIV-1 infected patients.

  • Use of the MQoL-HIV with asymptomatic HIV-positive patients. Smith, K. W.; Avis, N. E.; Mayer, K. H.; Swislow, L. // Quality of Life Research;Sep1997, Vol. 6 Issue 6, p555 

    The purpose of this study was to determine the appropriateness of the recently developed Multidimensional Quality of Life Questionnaire for HIV/AIDS (MQoL-HIV) as a measure of quality of life (QoL) in cases of asymptomatic human immunodeficiency virus (HIV) infection. The MQoL-HIV is a 40-item...

  • Epoetin alfa dosing schedule affects QOL in anaemic HIV patients.  // PharmacoEconomics & Outcomes News;1/17/2004, Issue 444, p10 

    Discusses research being done on the use of epoetin alfa in anaemic patients with HIV infections. Reference to a study by H. A. Grossman et al, published in the December 1, 2003 issue of the "Journal of Acquired Immune Deficiency Syndromes"; Quality of life in patients receiving epoetin alfa;...

  • QUALITY OF LIFE OF PEOPLE LIVING WITH HIV AND AIDS IN ESTONIA. Rüütel, Kristi; Uusküla, Anneli; Minossenko, Anastassia; Loit, Helle-Mai // Central European Journal of Public Health;2008, Vol. 16 Issue 3, p111 

    The assessment of quality of life is central to understanding how people's lives are affected by HIV infection. Estonia -- the smallest of three Baltic countries -- has experienced massive outbreak of HIV infection. Yet, little is known about the quality of life of HIV infected people in...

  • Associations of Symptoms and Health-Related Quality of Life: Findings from a National Study of... Lorenz, Karl A.; Shapiro, Martin F.; Asch, Steven M.; Bozzette, Samuel A.; Hayes, Ron D. // Annals of Internal Medicine;05/01/2001 Part 2, Vol. 134 Issue 9, p854 

    Estimates the association of symptoms of HIV infections with health-related quality of life and with disability days of HIV-positive persons. Use of health-related quality-of-life and disability days as measurements; Monotonic association between HIV-related symptoms, impaired functioning and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics